A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors
The decision to discontinue new enrollment is not related to any concerns about the safety
profile of the product.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with dose limiting toxicities (DLTs)
Each cycle (21 or 28 Days)
United States: Food and Drug Administration